MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
23.15
-0.31
-1.32%
Pre Market: 23.20 +0.05 +0.22% 07:01 01/09 EST
OPEN
23.23
PREV CLOSE
23.46
HIGH
24.12
LOW
22.90
VOLUME
207
TURNOVER
0
52 WEEK HIGH
129.84
52 WEEK LOW
10.42
MARKET CAP
2.43B
P/E (TTM)
-7.2625
1D
5D
1M
3M
1Y
5Y
1D
Is Sarepta (SRPT) Quietly Reframing Its CNS Strategy With The SRP-1005 Huntington’s Trial Move?
Simply Wall St · 19h ago
SAREPTA THERAPEUTICS INC <SRPT.O>: RBC RAISES TARGET PRICE TO $18 FROM $16
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Alcoa, BlackRock, Evercore
Reuters · 1d ago
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Rebound From Multi Year Lows
Simply Wall St · 1d ago
Sarepta Therapeutics Submits Clinical Trial Application For SRP-1005-101 For Huntington's Disease Treatment To New Zealand Medicines And Medical Devices Safety Authority; Intends To Start Trial Of SRP-1005 In Q2
Benzinga · 2d ago
SAREPTA THERAPEUTICS ANNOUNCES SUBMISSION OF CLINICAL TRIAL APPLICATION FOR SRP-1005, ITS INVESTIGATIONAL TREATMENT FOR HUNTINGTON’S DISEASE
Reuters · 2d ago
SAREPTA THERAPEUTICS INC - EXPECTS TO INITIATE SRP-1005 TRIAL IN Q2 2026
Reuters · 2d ago
Weekly Report: what happened at SRPT last week (1229-0102)?
Weekly Report · 4d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.